Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY6 | Q15077 | 6/20 | 0.52 |
| ▸ | P2RY14 | Q15391 | 2/20 | 0.52 |
| ▸ | NT5E | P21589 | 1/20 | 0.52 |
| ▸ | TYMP | P19971 | 7/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | ABL1 | P00519 | 1/20 | 0.41 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.41 |
| ▸ | P2RY2 | P41231 | 4/20 | 0.40 |
| ▸ | P2RY4 | P51582 | 3/20 | 0.40 |
| ▸ | ST6GAL1 | P15907 | 1/20 | 0.39 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30580338 | 0.95 | P2RY6 (0.51) | P2RY6P2RY14NT5ETYMPPOLB | |
| SCHEMBL1582637 | 0.94 | TYMP (0.48) | P2RY6P2RY14NT5ETYMPP2RY2 | |
| SCHEMBL17230913 | 0.94 | TYMP (0.48) | P2RY6P2RY14NT5ETYMPP2RY2 | |
| SCHEMBL18411645 | 0.94 | TYMP (0.48) | P2RY6P2RY14NT5ETYMPP2RY2 | |
| SCHEMBL6928957 | 0.92 | P2RY6 (0.55) | P2RY6P2RY14NT5ETYMPPOLB | |
| SCHEMBL6932433 | 0.89 | P2RY6 (0.52) | P2RY6P2RY14NT5ETYMPPOLB | |
| SCHEMBL17231044 | 0.88 | P2RY6 (0.43) | P2RY6P2RY14NT5ETYMPPOLB | |
| SCHEMBL31485531 | 0.88 | P2RY6 (0.55) | P2RY6P2RY14NT5ETYMPPOLB | |
| SCHEMBL6930742 | 0.87 | P2RY6 (0.51) | P2RY6P2RY14NT5ETYMPPOLB | |
| SCHEMBL3076277 | 0.87 | TYMP (0.45) | P2RY6P2RY14NT5ETYMPADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2217612-B9 | PREPARATION OF RIBONUCLEOTIDE OLIGOMER | ST PHARM CO LTD (KR) | 2016-02-10 | — | — | EP | disclosed |
| EP-2217612-B1 | PREPARATION OF RIBONUCLEOTIDE OLIGOMER | ST PHARM CO LTD (KR) | 2015-08-12 | — | — | EP | disclosed |
| US-8901289-B2 | Preparation of nucleotide oligomer | ST. PHARM CO., LTD. (KR) | 2014-12-02 | — | — | US | disclosed |
| US-20100273999-A1 | Preparation of Nucleotide Oligomer | SAMCHULLY PHARM. CO., LTD. (KR) | 2010-10-28 | — | — | US | disclosed |
| EP-2217612-A1 | PREPARATION OF NUCLEOTIDE OLIGOMER | Samchully Pharm. Co., Ltd. (KR) | 2010-08-18 | — | — | EP | disclosed |
| WO-2009064115-A1 | PREPARATION OF NUCLEOTIDE OLIGOMER | SAMCHULLY PHARM. CO., LTD. (KR) | 2009-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100273999-A1 | Preparation of Nucleotide Oligomer | NUDT1, SAMHD1, ADAR | P2RY6 229/4885P2RY14 296/4885NT5E 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.